Imatinib Mesylate-Induced Acquired Dermal Melanocytosis and Acquired Bilateral Nevus of Ota-Like Macules.

Dear Editor:

Imatinib mesylate, a tyrosine kinase inhibitor, is used for treatment of oncological conditions, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumor1. It inhibits tyrosine kinase encoded by the bcr-abl, c-kit, and platelet-derived growth factor receptor oncogenes23. The cutaneous adverse effects of imatinib are diverse, and rash and superficial edema are most common24. Pigmentary abnormalities are not common, although generalized skin hypopigmentation and vitiligo-like lesions are well-recognized5. Dermal melanocytosis associated with imatinib has been rarely reported.

A 48-year-old Asian female presented with bluish-to-greyish macules and patches on both temples; the left shoulder, and buttock. She had been treated with the same dose continuously with 400 mg of imatinib daily for 9 years for CML. She reported that facial pigmentation, which became gradually evident, appeared immediately after initiation of imatinib. Two years prior to the current presentation, the patient visited our clinic and underwent punch biopsy for the facial lesions (Fig. 1A). The histologic findings were consistent with acquired, bilateral nevus of Ota-like macules (ABNOM) with superficial dermal dendritic melanocytosis (Fig. 1C, D).

Fig. 1

(A) Ill-defined bluish to greyish colored patches on the bilateral temple. (B) Progressed facial lesions after 2 years. (C ,D) Dendritic dermal melanocytes in the upper dermis (C: H&E, ×100; D: Melan-A, ×200). (E, F) Bluish to greyish macules and patches on her both temples; left shoulder and buttock. (G, H) Sparsely distributed intradermal dendritic melanocytes in the mid to deep dermis (G: H&E, ×100; H: Melan-A, ×200).

Thereafter, seven years later, the shoulder and buttock lesions occurred (Fig. 1E, F), and she also complained that the facial lesions had become more prominent (Fig. 1B). She didn't report any subjective symptoms. Under the impression of acquired dermal melanocytosis (ADM) associated with imatinib, a skin biopsy was performed on the buttock. Histological examination revealed the presence of a sparse population of dendritic and stellate-shaped dermal melanocytes in the deep dermis based on hematoxylin- eosin staining (Fig. 1G). Immunohistochemically, these cells were positive for melan-A, S-100, and HMB-45 (Fig. 1H). Based on these clinicopathological findings, the patient was diagnosed with ADM. She underwent treatment with 1,064-nm Nd:YAG laser (SPECTRA XT™; Lutronic Corporation, Goyang, Korea) to her face, with a fluence setting of 30 J/cm2.

The pathophysiology of ADM remains unclear. It has been suggested that dermal melanocytes might migrate from the basal layer of the epidermis or the hair bulbs to dermis, or immature melanocytes could exist in the dermis due to migration failure from the neural crest to the basal layer during embryological development. ABNOM, a kind of ADM, is characterized by symmetrical blue-brown macules, most frequently involving facial lesions in Asian women with histopathological findings of irregularly-shaped bipolar melanocytes dispersed in the papillary and mid dermis, particularly in the subpapillary dermis. These dormant melanocytes could be later reactivated by various factors like inflammation, local trauma, sunlight, drugs, or hormonal stimulations12.

In our case, the patient complaint of blue-gray macules and patches on her face and trunk that appeared immediately after starting imatinib for CML treatment. Clinicopathologic findings were consistent with ABNOM induced by imatinib.

The mechanisms of imatinib-induced hyperpigmentation have been hypothesized that imatinib could have different target effects on immature and mature melanocytes, and that KIT and its ligand stem cell factor (SCF) play a critical role in the pathogenesis1. Imatinib-induced KIT/SCF blockage may cause epidermal depigmentation in mature melanocytes while influencing immature melanocytes to differentiate to produce melanin pigment causing hyperpigmentation1.

We received the patient's consent form about publishing all photographic materials.